Impax, Purdue strike deal on generic OxyContin

Share this article:

Impax Laboratories announced that it has reached an agreement with Purdue Pharma to settle all outstanding patent litigation surrounding Impax's generic version of the reformulated OxyContin that is now on the market.

In a statement, Impax said will have the right to market a specified number of bottles of its generic OxyContin under the agreement's terms, though that is contingent on the company getting final approval from the FDA on its Abbreviated New Drug Application (ANDA) for the drug. If Impax does not receive final ANDA approval for its generic version, it will still have the right to launch a specified number of bottles of an authorized generic version of OxyContin. In either case, the start date will be Jan. 1, 2016.

IMS Health data put US sales of OxyContin at approximately $2.6 billion for the 12 months ended September 2013.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.